Bartholomew the Apostle

ZEEL HELPS SCHOOLS SAY "THANK YOU" TO TEACHERS

Retrieved on: 
Mercoledì, Maggio 1, 2024
ZEEL, School, Health, Reward, Massage, Absenteeism, Bartholomew the Apostle, Associate, Back pain, MSK, Workplace, THANK, Parent, Tutoring

NEW YORK, May 1, 2024 /PRNewswire/ -- "An apple for teacher" may be a thing of the past because schools nationwide are stepping up their appreciation game. Zeel, the leading tech-enabled platform for bringing health and wellness services to the home and office, is working with thousands of schools to reward teachers during Teacher Appreciation Week, May 6-10, 2024.

Key Points: 
  • Zeel, the leading tech-enabled platform for bringing health and wellness services to the home and office, is working with thousands of schools to reward teachers during Teacher Appreciation Week, May 6-10, 2024.
  • Zeel offers the benefit of a chair massage in the workplace and/or the gift of an in-home massage to help reward and retain the nation's teachers.
  • "Year after year, ZEEL has generously allowed us to pamper our teachers during Teacher Appreciation Week with their amazing in-person massages and for this we say THANK YOU ZEEL!!
  • "Schools and their administrators want to make teachers feel appreciated for all they do," said Zeel CEO Samer Hamadeh.

ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Retrieved on: 
Lunedì, Gennaio 22, 2024
Bristol Myers Squibb, Neurophysiology, Patient, MD, Sanjay, Medicine, St Bartholomew's Hospital, Johns Hopkins Hospital, Johns Hopkins, Royal College of Physicians, Immunology, Saint Mary's Hospital, Acquisition, Royal college, Bachelor of Science, CMO, IPO, Bartholomew the Apostle, Fibrosis, Hospital, Series A round, FRCP, Roche, Faricimab, Growth, Pharmaceutical industry

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
  • Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies.
  • "As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain.
  • I am privileged to work with the ImmunoBrain team and Professor Michal Schwartz whose groundbreaking seminal research has formed the foundation of ImmunoBrain," stated Dr. Sanjay Keswani.

Health care culture expert to headline RISE's 22nd Risk Adjustment Forum

Retrieved on: 
Martedì, Ottobre 31, 2023
HCC, Affordable Care Act, Centers for Medicare & Medicaid Services, Education, Medicare, Medicare Advantage, Risk-adjusted return on capital, Risk, Medicaid, Culture, Communication, Mobile phone, DALLAS, Bartholomew the Apostle

 DALLAS, Oct. 31, 2023 /PRNewswire/ -- Kathleen Bartholomew, R.N., MN, named one of the top 20 people changing health care in America, will be the keynote speaker at the 22nd Risk Adjustment Forum, the premier event for risk adjustment and quality specialists in the health care industry, which will take place November 27-29, 2023, at the Fairmont Dallas.

Key Points: 
  • Kathleen Bartholomew, R.N., MN, an expert on the power of culture, will kick off the first day of the main conference with a presentation on how to lead through change.
  • DALLAS, Oct. 31, 2023 /PRNewswire/ -- Kathleen Bartholomew, R.N., MN, named one of the top 20 people changing health care in America, will be the keynote speaker at the 22nd Risk Adjustment Forum , the premier event for risk adjustment and quality specialists in the health care industry, which will take place November 27-29, 2023, at the Fairmont Dallas.
  • The three-day Risk Adjustment Forum, which includes four pre-conference workshops, is designed for executives in Medicare Advantage, Medicaid managed care, and Affordable Care Act plans who seek updated best practices and strategies for coding accuracy and education success.
  • The Risk Adjustment Forum will take place November 27-29, 2023, at the Fairmont Dallas.

Avricore’s HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Retrieved on: 
Giovedì, Agosto 3, 2023
Blood pressure, Heart, Royal London Hospital, Whipps Cross, Pharmacy, Heart failure, Bartholomew the Apostle, Cholesterol, HEART, Moyamoya disease, COVID-19, Cardiovascular disease, St Bartholomew's Hospital, England, Arrhythmia, Royal London, Hypertension, Death, Pharmacist, City, Patient, OTC, Health, Conditional sentence, Hospital, NHS England, NHS, Pharmaceutical industry

That initiative allowed those with high blood pressure to be identified and referred onward for management.

Key Points: 
  • That initiative allowed those with high blood pressure to be identified and referred onward for management.
  • The collaborative leading the feasibility study include:
    Barts Heart Centre – Is at the forefront of new treatments for heart disease and is proud that its patients have some of the best clinical outcomes in the country.
  • It treats patients from across the UK for a wide range of complex conditions including coronary heart disease, arrhythmias, heart failure and many other cardiac problems.
  • HEART UK - The UK’s only cholesterol charity, providing support, information and influencing services for families and health professionals.

Clinical ink Announces Jonathan Goldman as New Chief Executive Officer

Retrieved on: 
Lunedì, Febbraio 13, 2023
Bartholomew the Apostle, St. Bartholomew's, MBBS, Berkeley, University of California, San Francisco, Diagnosis, Chattogram Maa-O-Shishu Hospital Medical College, Columbia University, Patient, Hospital, HIV disease progression rates, University, Saint George, ICON PLC, GI Partners, Bachelor of Science, ESourcing Capability Model, Jeff Jacobson (CEO), Military, MD, Pharmaceutical industry, Nursing, Dermatology, Oncology, Cardiology, Medicine, Neuroscience

HORSHAM, Pa., Feb. 13, 2023 /PRNewswire/ -- Clinical ink, a global life science technology company, today announced that experienced healthcare industry veteran Dr. Jonathan Goldman MD has joined the company as Chief Executive Officer (CEO). Jonathan succeeds Ed Seguine who has led Clinical ink since nearly fourteen years ago.

Key Points: 
  • HORSHAM, Pa., Feb. 13, 2023 /PRNewswire/ -- Clinical ink, a global life science technology company, today announced that experienced healthcare industry veteran Dr. Jonathan Goldman MD has joined the company as Chief Executive Officer (CEO).
  • Jonathan brings unique medical insights and clinical development experience to deliver Clinical Ink's innovative eSource platform."
  • "Dr. Goldman's background in medicine is the perfect complement to Clinical ink's innovative technology expertise," commented Ed Seguine, former CEO of Clinical ink.
  • Jonathan has 30 years of experience across life sciences as a CEO, Chief Medical Officer, Investor, and senior executive.

Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics

Retrieved on: 
Mercoledì, Settembre 15, 2021
Immunotherapy, Business, Corporate finance, Cancer, New York University Stern School of Business, Therapy, Board, Drug development, Associate, Uppsala University, Bachelor of Science, Janssen, Karolinska University Hospital, Transfusion medicine, Patient, Johnson & Johnson, Director, Medicine, Immunology, Karolinska Institute, Leadership, NK, Hospital, MBA, St Bartholomew's Hospital, NHS, Research, FFPM, Bartholomew the Apostle, Uppsala University Hospital, Management, Pharmaceutical industry

STOCKHOLM, Sept. 15, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors.

Key Points: 
  • STOCKHOLM, Sept. 15, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors.
  • "We are incredibly pleased to be able attract such dedicated life science professionals as David and Stephen to the board.
  • "I'm delighted to be nominated to the board of XNK Therapeutics.
  • "It is an honor to be asked to join the board of XNK," said Dr. Wooding.

Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics

Retrieved on: 
Mercoledì, Settembre 15, 2021
Immunotherapy, Business, Corporate finance, Cancer, New York University Stern School of Business, Therapy, Board, Drug development, Associate, Uppsala University, Bachelor of Science, Janssen, Karolinska University Hospital, Transfusion medicine, Patient, Johnson & Johnson, Director, Medicine, Immunology, Karolinska Institute, Leadership, NK, Hospital, MBA, St Bartholomew's Hospital, NHS, Research, FFPM, Bartholomew the Apostle, Uppsala University Hospital, Management, Pharmaceutical industry

STOCKHOLM, Sept. 15, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors.

Key Points: 
  • STOCKHOLM, Sept. 15, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors.
  • "We are incredibly pleased to be able attract such dedicated life science professionals as David and Stephen to the board.
  • "I'm delighted to be nominated to the board of XNK Therapeutics.
  • "It is an honor to be asked to join the board of XNK," said Dr. Wooding.

Medtronic Announces NAVABLATE Study Results Released in Late-Breaking Podium Presentation at European Respiratory Society International Congress 2021

Retrieved on: 
Martedì, Settembre 7, 2021

DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the NAVABLATE study, which highlights the much anticipated safety and performance results on microwave ablation used bronchoscopically with the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology in conjunction with the Medtronic electromagnetic navigation bronchoscopy system. Results were reported as a late-breaking presentation at the virtual European Respiratory Society International Congress 2021, September 5, 2021.

Key Points: 
  • Results were reported as a late-breaking presentation at the virtual European Respiratory Society International Congress 2021, September 5, 2021.
  • NAVABLATE is a prospective, multi-center study that enrolled 30 subjects in the United Kingdom and Hong Kong to characterize the safety and performance of the CE Marked Emprint Ablation Catheter Kit.
  • All patients underwent a bronchoscopic ablation procedure using the Emprint Ablation Catheter Kit and were followed for one month post procedure.
  • The composite rate of adverse events related to the Emprint Ablation Catheter Kit was 3.3% (one subject with mild hemoptysis).